Dahan Michel's Form 4 filing
Akebia Therapeutics, Inc. (AKBA) · filed May 14, 2024
- Accession no.
- 0001562180-24-004025
- Filed
- May 14, 2024
- Trade date
- May 13, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market sales total $43.9K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dahan MichelCIK 0001669737 | Officer (SVP, Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 13, 2024 | Common Stock | SSaleDisposed | −34,840 | $1.26 | −$43,898.4 | 672,092 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.